Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. Therefore, the hepatitis-B vaccines are cancer-preventing vaccines. According to the Centers for Disease Control and Prevention (CDC), the hepatitis B vaccine was the first anti-cancer vaccine.[5] (en)
|
http://linked.open...y/drugbank/dosage
| |
http://linked.open...generalReferences
| - # Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, Lok AS: Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology. 1998 Jan;27(1):213-22. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9425940 (en)
|
http://linked.open...gy/drugbank/group
| - approved (en)
- investigational (en)
|
http://linked.open...ugbank/indication
| - Investigated for use/treatment in hepatitis (viral, B), liver transplant surgery, and pediatric indications. (en)
|
sameAs
| |
Title
| - hepatitis B immune globulin (en)
|
adms:identifier
| |
http://linked.open...mechanismOfAction
| - In countries with high rates of hepatitis B infection, vaccination of newborns has not only reduced the risk of infection, but has also led to marked reduction in liver cancer. (en)
|